JORGE E CORTES to Hypereosinophilic Syndrome
This is a "connection" page, showing publications JORGE E CORTES has written about Hypereosinophilic Syndrome.
Connection Strength
1.121
-
Therapeutic options for patients with clonal and idiopathic hypereosinophia. Expert Opin Investig Drugs. 2008 Jul; 17(7):1039-50.
Score: 0.300
-
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003 Jun 15; 101(12):4714-6.
Score: 0.207
-
Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):287-91.
Score: 0.101
-
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009 Jan 01; 15(1):368-73.
Score: 0.078
-
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2009 Jun; 33(6):837-9.
Score: 0.077
-
Pregnancy in a patient with hypereosinophilic syndrome. Leuk Res. 2009 Jan; 33(1):186-7.
Score: 0.075
-
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia. 2007 Jul; 21(7):1395-404.
Score: 0.069
-
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 01; 104(3):541-6.
Score: 0.061
-
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27; 348(13):1201-14.
Score: 0.052
-
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002 Sep; 26(9):881-4.
Score: 0.050
-
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007 Nov 01; 110(9):2012-8.
Score: 0.018
-
Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2006 Sep; 38(5):393-4.
Score: 0.016
-
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res. 2006 Dec; 30(12):1499-505.
Score: 0.016